Hasan Tolga ÇELİK, Murat YURDAKÖK, Şule YİĞİT, Ayşe KORKMAZ

Does inhaled salbutamol before surfactant therapy have any beneficial effect?

Beta (β)2 adrenergic receptors are present in alveolar type II cells. Previously,the beneficial effects of inhaled salbutamol treatment on respiratory outcomeswere shown in premature infants with transient tachypnea of the newborn. Wehypothesized that inhaled salbutamol would increase the effects of surfactanton oxygenation in premature infants with respiratory distress syndrome(RDS). Inhaled salbutamol (0.15 mg/kg) or normal saline solution (0.30 ml/kg) was administered as a single dose by micropump nebulizer 10 minutesbefore the first dose of surfactant (Poractant alfa) treatment in 40 infantswith gestational ages ranging from 26 to 36 weeks. The effects of salbutamoltherapy were evaluated by determining the duration of respiratory support,number of doses of surfactant, respiratory rate, heart rate, fraction of inspiredoxygen, and partial pressure of arterial oxygen before and after salbutamolnebulization. No statistically significant difference was detected between thetwo groups in duration of respiratory support, number of doses of surfactant,respiratory rate, fraction of inspired oxygen, or partial pressure of arterialoxygen. In this study, no significant effect of inhaled salbutamol treatmenton the surfactant therapy in premature infants with RDS was detected.

PDF

___

Rubaltelli FF, Dani C, Reali MF, et al. Acute neonatal respiratory distress in Italy: A one-year prospective study. Italian Group of Neonatal Pneumology. Acta Paediatr 1998; 87: 1261-1268.
Speer CP, Sweet DG, Halliday HL. Surfactant therapy: Past, present and future. Early Hum Dev 2013; 89 (Suppl 1): S22-S24.
Ng G, da Silva O, Ohlsson A. Bronchodilators for the prevention and treatment of chronic lung disease in preterm infants. Cochrane Database Syst Rev 2012; 6: CD003214.
Lee H, Arnon S, Silverman M. Bronchodilator aerosol administered by metered dose inhaler and spacer in subacute neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed 1994; 70: F218-F222.
Hilgendorff A, Reiss I, Gortner L, Schüler D, Weber K, Lindemann H. Impact of airway obstruction on lung function in very preterm infants at term. Pediatr Crit Care Med 2008; 9: 629-635.
Mhanna MJ, Patel JS, Patel S, Cohn R. The effects of racemic albuterol versus levalbuterol in very low birth weight infants. Pediatr Pulmonol 2009; 44: 778-783.
Armangil D, Yurdakök M, Korkmaz A, Yiğit S, Tekinalp G. Inhaled beta-2 agonist salbutamol for the treatment of transient tachypnea of the newborn. J Pediatr 2011; 159: 398-403.e1.
Johnson M. Molecular mechanisms of beta(2)-adrenergic receptor function, response, and regulation. J Allergy Clin Immunol 2006; 117: 18-24.
Nelson HS. Beta-adrenergic bronchodilators. N Engl J Med 1995; 333: 499-506.
Schumacher W, Mirkin BL, Sheppard JR. Biological maturation and beta-adrenergic effectors: Development of beta-adrenergic receptors in rabbit heart. Mol Cell Biochem 1984; 58: 173-181.